107P Health-related quality of life with ivonescimab versus pembrolizumab for PD-L1 positive, non-small cell lung cancer (HARMONi-2): A randomised, double-blind, phase III study in China

Key Points

• The aim is to compare health-related quality of life between ivonescimab and pembrolizumab in patients with PD-L1 positive NSCLC.
• Randomised, double-blind, phase III study design
• Participants were previously untreated patients with advanced PD-L1 positive NSCLC
• Comparison of health-related quality of life outcomes between treatments
• Ivonescimab significantly improved progression-free survival compared to pembrolizumab
• Safety profile of ivonescimab was manageable
• Health-related quality of life data were reported from the study